Gary Landucci
Overview
Explore the profile of Gary Landucci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
3006
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prakash S, Dhanushkodi N, Singer M, Quadiri A, Zayou L, Vahed H, et al.
bioRxiv
. 2024 Feb;
PMID: 38405942
The first-generation Spike-alone-based COVID-19 vaccines have successfully contributed to reducing the risk of hospitalization, serious illness, and death caused by SARS-CoV-2 infections. However, waning immunity induced by these vaccines failed...
2.
Dhanushkodi N, Prakash S, Quadiri A, Zayou L, Srivastava R, Shaik A, et al.
J Immunol
. 2024 Jan;
212(4):576-585.
PMID: 38180084
SARS-CoV-2 variants of concern (VOCs) continue to evolve and reemerge with chronic inflammatory long COVID sequelae, necessitating the development of anti-inflammatory therapeutic molecules. Therapeutic effects of the receptor for advanced...
3.
Huang Y, Ferrari G, Alter G, Forthal D, Kappes J, Lewis G, et al.
J Immunol
. 2016 Dec;
197(12):4603-4612.
PMID: 27913647
Diverse Ab effector functions mediated by the Fc domain have been commonly associated with reduced risk of infection in a growing number of nonhuman primate and human clinical studies. This...
4.
Asbach B, Kliche A, Kostler J, Perdiguero B, Esteban M, Jacobs B, et al.
J Virol
. 2016 Feb;
90(8):4133-4149.
PMID: 26865719
Unlabelled: In a follow-up to the modest efficacy observed in the RV144 trial, researchers in the HIV vaccine field seek to substantiate and extend the results by evaluating other poxvirus...
5.
Hicar M, Chen X, Kalams S, Sojar H, Landucci G, Forthal D, et al.
Mol Immunol
. 2016 Jan;
70:94-103.
PMID: 26748387
Neutralizing antibodies (Abs) are thought to be a critical component of an appropriate HIV vaccine response. It has been proposed that Abs recognizing conformationally dependent quaternary epitopes on the HIV...
6.
Santra S, Tomaras G, Warrier R, Nicely N, Liao H, Pollara J, et al.
PLoS Pathog
. 2015 Aug;
11(8):e1005042.
PMID: 26237403
HIV-1 mucosal transmission begins with virus or virus-infected cells moving through mucus across mucosal epithelium to infect CD4+ T cells. Although broadly neutralizing antibodies (bnAbs) are the type of HIV-1...
7.
Chukwuma V, Hicar M, Chen X, Nicholas K, Joyner A, Kalams S, et al.
PLoS One
. 2015 Jul;
10(7):e0133509.
PMID: 26226263
The human antibody response against HIV-1 infection recognizes diverse antigenic subunits of the virion, and includes a high level of antibodies to the Gag protein. We report here the isolation...
8.
Venditto V, Wieczorek L, Molnar S, Teque F, Landucci G, Watson D, et al.
Clin Vaccine Immunol
. 2014 May;
21(8):1086-93.
PMID: 24872518
Broadly neutralizing monoclonal antibodies (bNAbs) 2F5 and 4E10 bind to the membrane proximal external region (MPER) of gp41 and also cross-react with phospholipids. In this study, we investigated if chemical...
9.
Gupta S, Pegu P, Venzon D, Gach J, Ma Z, Landucci G, et al.
J Infect Dis
. 2014 May;
211(1):45-52.
PMID: 24850790
Background: The time to acquisition of simian immunodeficiency virus (SIV) infection following low-dose repeated rectal challenge correlated inversely with the number of transmitted/founder strains among macaques vaccinated with ALVAC-SIV/gp120 or...
10.
Gach J, Achenbach C, Chromikova V, Berzins B, Lambert N, Landucci G, et al.
PLoS One
. 2014 Jan;
9(1):e85371.
PMID: 24454852
The majority of potent and broadly neutralizing antibodies against HIV-1 have been isolated from untreated patients with acute or chronic infection. To assess the extent of HIV-1 specific antibody response...